Pages that link to "Q33437467"

The following pages link to Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol (Q33437467):

Displaying 27 items.

• Biomedical and biochemical applications of liquid chromatography-mass spectrometry (Q28292448) (← links)
• Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol (Q28346985) (← links)
• Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond (Q30955390) (← links)
• Analysis of citrulline in rat brain tissue after perfusion with haloperidol by liquid chromatography-mass spectrometry. (Q33422399) (← links)
• Pharmacokinetics of haloperidol: an update (Q33813315) (← links)
• Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem (Q34738217) (← links)
• Minimising the potential for metabolic activation in drug discovery (Q36572637) (← links)
• Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one (Q37147674) (← links)
• Role of haloperidol in palliative medicine: an update (Q37945595) (← links)
• Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid (Q40222308) (← links)
• Contribution of amine oxidases to the metabolism of xenobiotics (Q40632139) (← links)
• Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice (Q42841690) (← links)
• Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats (Q44317363) (← links)
• Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients (Q44680500) (← links)
• Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations (Q44894528) (← links)
• Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. (Q45115174) (← links)
• Binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a metabolite of haloperidol, to synthetic melanin: implications for the dopaminergic neurotoxicity of HPP+. (Q45216748) (← links)
• Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study (Q46677709) (← links)
• QSAR modeling and transmission electron microscopy stereology of altered mitochondrial ultrastructure of white blood cells in patients diagnosed as schizophrenic and treated with antipsychotic drugs (Q47688049) (← links)
• Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter (Q47894341) (← links)
• Determination of 1-methyl-1,2,3,4-tetrahydroisoquinoline in mouse brain after treatment with haloperidol by gas chromatography-selected ion monitoring (Q48109941) (← links)
• Invariom based electron density studies on the C/Si analogues haloperidol/sila-haloperidol and venlafaxine/sila-venlafaxine. (Q52863798) (← links)
• Metabolic defects caused by treatment with the tetrahydropyridine analog of haloperidol (HPTP), in baboons (Q73497917) (← links)
• Metabolic defects caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and by HPTP (the tetrahydropyridinyl analog of haloperidol), in rats (Q73814087) (← links)
• Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? (Q73942975) (← links)
• p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol (Q78170745) (← links)
• Mass spectrometry in pharmaceutical analysis 1 * (Q84073928) (← links)